Table 3.
Characteristics of the study participants
| Study participants (n = 29) | |
|---|---|
| Age, years | 52 ± 9 |
| Female | 11 (38%) |
| Baseline PRA, ng/mL/hr | 1.3 (0.5–3.1) |
| Number of antihypertensive drug classes at baseline | |
| 1 Anti‐V | 6 (21%) |
| 1 Anti‐R | 9 (31%) |
| 2 Anti‐R | 2 (7%) |
| 1 Anti‐V + 1 anti‐R | 4 (14%) |
| 1 Anti‐V + 2 anti‐R | 4 (14%) |
| 2 Anti‐V + 1 anti‐R | 1 (3%) |
| None | 3 (10%) |
Age is summarized as mean ± SD, PRA as median (interquartile range), and categorical variables as N (percentage).
Anti‐V (anti‐volume) drugs including diuretics, aldosterone receptor antagonists, calcium channel blockers, vasodilators, and α1‐blockers; Anti‐R (anti‐renin) drugs including angiotensin converting enzyme inhibitors, angiotensin receptor blockers, β‐blockers, direct renin inhibitors, and central α2‐agonists; PRA, plasma renin activity.